Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II topline data show efficacy of MS-1819 plus PERT in severe exocrine pancreatic insufficiency

Aug. 19, 2021

YAP/TEAD expression defines distinct vulnerabilities in binary pan-cancer groups

Aug. 19, 2021

ExeVir's COVID-19 treatment and prophylactic XVR-011 enters clinical study

Aug. 18, 2021

Pirfenidone shows favorable effects in patients with HFpEF

Aug. 18, 2021

HER2 expression is a prognostic factor in DCIS

Aug. 18, 2021

Ganaxolone reduces seizure frequency in tuberous sclerosis complex patients

Aug. 18, 2021

Preclinical toxicology study supports development of antidiarrheal lechlemer

Aug. 18, 2021

Phase I study of Alzheimer's disease candidate AL-001 to begin in September

Aug. 18, 2021

Transcenta begins phase II trial of TST-001 in solid tumors

Aug. 18, 2021

Istari Oncology expands LUMINOS-103 trial of PVSRIPO to include HNSCC

Aug. 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...